A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Dose-Response Relationships of Acid-Inhibitory Effect and Efficacy of TAK-438 (20 mg, 40 mg) in Patients with PPI-Resistant Erosive Esophagitis.
Phase of Trial: Phase III
Latest Information Update: 24 May 2016
At a glance
- Drugs Vonoprazan (Primary)
- Indications Reflux oesophagitis
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 24 May 2016 Results presented at the Digestive Disease Week 2016
- 07 Feb 2014 According to the ClinicalTrials.gov record, status changed to completed.
- 03 Jul 2012 New trial record